Rafivirumab

Rafivirumab (CR57) is a monoclonal antibody for the prophylaxis of rabies.[1][2][3]

Rafivirumab
Monoclonal antibody
TypeWhole antibody
SourceHuman
Targetrabies virus glycoprotein
Clinical data
ATC code
  • none
Identifiers
CAS Number
ChemSpider
  • none
UNII
Chemical and physical data
FormulaC6462H9954N1718O2036S46
Molar mass145761.46 g·mol−1
 NY (what is this?)  (verify)

References
  1. "International Nonproprietary Names for Pharmaceutical Substances (INN)" (PDF). World Health Organization.
  2. Kramer RA, Marissen WE, Goudsmit J, Visser TJ, Clijsters-Van der Horst M, Bakker AQ, et al. (July 2005). "The human antibody repertoire specific for rabies virus glycoprotein as selected from immune libraries". European Journal of Immunology. 35 (7): 2131–45. doi:10.1002/eji.200526134. PMID 15971273.
  3. Franka R, Carson WC, Ellison JA, Taylor ST, Smith TG, Kuzmina NA, et al. (September 2017). "In Vivo Efficacy of a Cocktail of Human Monoclonal Antibodies (CL184) Against Diverse North American Bat Rabies Virus Variants". Tropical Medicine and Infectious Disease. 2 (3): 48. doi:10.3390/tropicalmed2030048. PMC 6082099. PMID 30270905.
This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.